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Research Article
First-in-Man Evaluation of 124I-PGN650: A PET
Tracer for Detecting Phosphatidylserine
as a Biomarker of the Solid Tumor
Microenvironment
Richard Laforest, PhD1,2,3, Farrokh Dehdashti, MD2,3, Yongjian Liu, PhD1,2,
Jennifer Frye, CMMT3, Sarah Frye, CMMT3, Hannah Luehmann1, Deborah Sultan1,
Joseph S. Shan, PhD4, Bruce D. Freimark, PhD4, and Barry A. Siegel, MD2,3
Abstract
Purpose: PGN650 is a F(ab0)2 antibody fragment that targets phosphatidylserine (PS), a marker normally absent that becomes
exposed on tumor cells and tumor vasculature in response to oxidative stress and increases in response to therapy. PGN650 was
labeled with 124I to create a positron emission tomography (PET) agent as an in vivo biomarker for tumor microenvironment and
response to therapy. In this phase 0 study, we evaluated the pharmacokinetics, safety, radiation dosimetry, and tumor targeting of
this tracer in a cohort of patients with cancer.
Methods: Eleven patients with known solid tumors received approximately 140 MBq (3.8 mCi) 124I-PGN650 intravenously and
underwent positron emission tomography–computed tomography (PET/CT) approximately 1 hour, 3 hours, and either 24 hours
or 48 hours later to establish tracer kinetics for the purpose of calculating radiation dosimetry (from integration of the organ
time-activity curves and OLINDA/EXM using the adult male and female models).
Results: Known tumor foci demonstrated mildly increased uptake, with the highest activity at the latest imaging time. There were
no unexpected adverse events. The liver was the organ receiving the highest radiation dose (0.77 mGy/MBq); the effective dose
was 0.41 mSv/MBq.
Conclusion: Although 124I-PGN650 is safe for human PET imaging, the tumor targeting with this agent in patients was less than
previously observed in animal studies.
Keywords
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Introduction
Phosphatidylserine (PS) is a cell membrane glycerophospholi-
pid. The PS molecules normally face the cell interior but flip to
the outer surface of cells during cellular stress, apoptosis,
necrosis, and in response to stress conditions such as hypoxia,
acidity, thrombin, inflammatory cytokines, and reactive oxy-
gen species, which all occur in the tumor microenvironment.
Thus, a PS targeting antibody could have widespread applic-
ability as a noninvasive, in vivo imaging agent in both experi-
mental animal models and in human diseases, including
diabetes, cardiovascular disease,1,2 and in particular cancer.3,4
Oncology is a particularly compelling field of interest since
many treatment approaches, including chemotherapy and
radiotherapy, enhance PS exposure on cell membranes of
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tumor endothelium and tumor cells.5-7 PS imaging could be
employed as a general cancer imaging agent for detection,
staging, and treatment monitoring,8 including therapeutic
approaches specifically designed to induce cancer cell apopto-
sis.9,10 Early detection of PS exposure would provide the
needed evidence to continue treatment and, conversely, the
lack of an early effect could lead to a change in the treatment
drug. A PS imaging agent would also be useful to assess the
adequacy of dosing and to predict the likelihood of response
with a PS-targeted therapy, such as the recently developed PS-
targeting antibody bavituximab.11
PGN650 is a F(ab0)2 antibody fragment derived by pepsin
digestion of a fully human immunoglobulin IgG1 (PGN635)
that targets PS in tumors. Both PGN650 and bavituximab target
exposed PS on tumors with high affinity, using a similar com-
plexation with the circulating protein b-2 glycoprotein 1. Bavi-
tuximab has higher specificity for PS than does annexin V and
higher affinity than many lower-molecular-weight molecules
known to bind PS.12 In preclinical studies, PGN650 has been
used to image human tumor xenografts in mice with near-
infrared (NIR) optical imaging and positron emission tomogra-
phy (PET). The NIR dye-labeled PGN650 injected in mice with
subcutaneous human U87 glioma tumors had a tumor to normal
tissue probe ratio (TNR) of 2.5 at 24 hours postinjection.13
Treatment of subcutaneous tumors with 12 Gy irradiation
enhanced tumor uptake of NIR dye-labeled PGN650 with a
TNR of 4.0 at 24 hours. Treatment of mice bearing orthotopic
BT-474 human breast tumors with docetaxel enhanced NIR
dye-labeled PGN650 uptake compared to untreated tumors.4
124I-labeled PGN650 was shown to have similar binding activ-
ity in vitro compared to unlabeled PGN650 and to target human
PC-3 subcutaneous and orthotopic tumors in mice as demon-
strated by microPET.14 Histological evaluation of tumor-
bearing mice treated with NIR-labeled PGN650 showed that
the imaging agent targeted tumor vasculature and tumor
cells.4,13 The purpose of article is to report on a first-in-man
study, describing the pharmacokinetics, safety, radiation dosi-




The 124I (half-life ¼ 4.18 days, 22.9% bþ emission) was pro-
duced by 3D Imaging (Little Rock, Arkansas) via a
124Te(p,n)124I reaction. The percentage of iodide versus iodate
was verified prior to radiolabeling via radio thin-layer chroma-
tography. [124I]NaI (10-15 mCi) buffered with 100 mM
Na2HPO4 in 150 mM NaCl, pH 7.2 was added to 1.0 mg
PGN650 buffered in 1 phosphate-buffered saline in the pres-
ence of 2 Iodogen beads (Fisher Science Education) in a bor-
osilicate vial. The reaction was allowed to incubate at room
temperature for 10 minutes followed by size-exclusion purifi-
cation using a PD-10 desalting column. Fractions collected
from the column with a radiochemical purity 95% were
combined and transferred to a current Good Manufacturing
Practice(cGMP) facility for sterile filtration and quality control
testing. Preclinical use evaluations included radionuclidic iden-
tity, appearance and color, pH, filter membrane integrity, spe-
cific activity, radioactivity, radiochemical purity, strength, and
bacterial endotoxin. Postclinical release testing included mass,
chemical purity, identity, sterility, environment profile, radio-
chemical purity, and specific binding.
Patient Population
This study was conducted under an investigational new drug
application (IND #115106, clinicaltrials.gov #NCT01632696)
and approved by the institutional review board of Washington
University School of Medicine. All patients provided written
informed consent. Eleven patients (18 years) were studied.
Eligible patients needed to have a biopsy-proven solid malig-
nant tumor, an estimated life expectancy <5 years and at least 1
measurable tumor site as defined by Response Evaluation Cri-
teria in Solid Tumors 1.1,15 but with the specific modification
for this PET protocol of a minimum tumor diameter of 1.5
cm. The median time lapse from the last chemotherapy to the
injection of 124I-PGN650 in our patient population was 26 days
(range 5-526 days).
Animal Biodistribution and Dosimetry
Human radiation dosimetry estimates for 124I-PGN650 were
calculated from animal biodistribution data obtained by stan-
dard organ dissection method and were based on Medical Inter-
nal Radiation Dosimetry (MIRD) methodology. Normal
C57BL/c male and female mice were injected with 9 mCi/100
mL of 131I-PGN650 and euthanized at 1, 6, 12, 24, 48, 72, 96,
and 144 hours following injection to establish the tracer bio-
distribution. Urinary and fecal excretion data were collected by
placing the animals in metabolic cages. At these time points,
normal organs were dissected, weighed, and counted for activ-
ity. Time-activity curves were created and normal organ resi-
dence times were calculated. The organ residence times were
scaled to those for humans by the human to mouse relative
organ weight method,16 and the residence times were then
entered into OLINDA/EXM version 1.117 to calculate radiation
dose estimates for the human male and human female anthro-
pomorphic models. The whole-body clearance (biological half-
life) was measured by fitting a monoexponential decay func-
tion to the plot of the sum of the percentage injected dose (ID)
in all organs as a function of time.
Human Imaging Studies
All PET imaging was performed with a Siemens Biograph-40
positron emission tomography/computed tomography (PET/
CT) scanner (Siemens Heathineers, Knoxville, Tennessee).
The planned dosage of approximately 140 MBq (3.8 mCi) of
124I-PGN650 was administered over 5 minutes, after which
patients were imaged at approximately 1 hour, *3 hours, and
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at either 24 hours or 48 hours post-injection by a whole-body
PET procedure from head to upper thigh. In order to limit
radiation exposure to the thyroid that could result from the
formation of free 124I-iodide by the metabolism of 124I-
PGN650, patients received saturated potassium iodide solution,
2 drops orally 3 times per day, beginning 1 hour before 124I-
PGN650 administration, for a total of 8 days. At each imaging
session, a spiral CT for attenuation correction (120 kVp, 50
mAs effective) was obtained from the top of the skull through
the upper thighs, with the patient supine. Immediately after the
attenuation CT scan, emission images beginning at the top of
the skull and proceeding caudally through the upper thighs
were obtained (1-10 minutes per bed position). Imaging was
performed over 6 to 7 bed positions with a total imaging dura-
tion of no more than 1 hour. Images were reconstructed with
3D-Ordered-Subset Estimation-Maximization (OSEM) with 3
iterations, 24 subsets, and a post-reconstruction Gaussian filter
of 5 mm.
Image Analysis
All images were evaluated subjectively by one observer for
focal areas of abnormally increased uptake in the known sites
of tumors and semiquantitatively using the maximum standar-
dized uptake value (SUVmax) and tumor to blood ratio (T/B).
The T/B ratio was determined by dividing the maximum counts
of the tumor by the average counts of the blood pool. The
overall image quality was graded as adequate to inadequate.
Human Dosimetry Calculations
Normal human dosimetry estimates were calculated from phar-
macokinetic data obtained from whole-torso PET images.
Regions of interests (ROIs) were drawn on the major organs
as visible on the PET images, including liver, kidneys, blood
pool (left ventricle), spleen, muscle, and thyroid. The total
activity in the organ was calculated by scaling the measured
organ activity concentrations to the standard adult organ
weight. Analytical integration of monoexponential fits with the
measured time-activity curves provided the organ residence
times. Blood activity concentration was estimated from the left
ventricular ROI. Total blood volume was estimated in accor-
dance with Pearson et al.18 Human dosimetry estimates were
obtained from the residence times and OLINDA/EXM soft-
ware (version 1.1, Vanderbuilt University) using the adult male
and female models. Organ time-activity curves for every
patient were collated to create average cumulative times curves
from which average dosimetry estimates to normal adult
human population were estimated. Bone marrow residence
time was estimated from the blood residence time by the
method of Wessels et al.19 The left ventricle was assumed to
contain 550 mL of blood and the lung blood volume was
assumed to be 300 mL. Total activity accumulated in the urin-
ary bladder was tallied and plotted over time. These data were
then fitted by an uptake function f(t) ¼ Ao (1exp[lBladder
t]), with Ao the bladder filling fraction and lBladder the filling
half-life. The bladder filling fraction and filling time were then
used with the bladder voiding model in OLINDA/EXM,
assuming a 2-hour voiding interval to estimate the residence
time of urine in the bladder. A large ROI was drawn over the
whole patient torso to evaluate the total activity within each
patient at each imaging time points. The total torso residence
time was obtained by analytical integration of a monoexponen-
tial fit on the whole-torso activity time-activity curve. The
excreted activity (not observed in the urinary bladder) was
obtained by subtracting this value from the maximum theore-
tical residence time (defined by the 124I half-life/ln[2] and
equal to 144.6 hours). The remainder of the body residence
time was determined from the maximum theoretical residence
time minus the whole torso and excreted residence times.
Safety Evaluation
All patients underwent measurement of vital signs (blood pres-
sure, heart rate, respiratory rate, and temperature), clinical
laboratory testing (standard hematologic and comprehensive
metabolic panels that included hemoglobin, white blood cells,
neutrophils, lymphocytes, platelets, creatinine, blood urea
nitrogen, calcium, sodium, potassium, carbon dioxide, alanine
transaminase, aspartate aminotransferase, alkaline phospha-
tase, total bilirubin, and albumin), urinalysis, and electrocar-
diography before 124I-PGN650 administration and at the third
imaging session (24 or 48 hours after injection).
Results
Tracer Production, Labeling, and Safety
Patient doses (n ¼ 11) were successfully prepared following
cGMP guidelines in a straightforward labeling synthesis with a
simple purification strategy and robust quality control. Deliv-
ered activities of 124I-PGN650 ranged from 137 to 263 MBq
(mean 211 MBq). Radiochemical purity of the final product
was 97 to 100%. The specific activity of the 124I-PGN650 doses
averaged 403 MBq/mg. The mass of injected tracer was 0.64
(0.13) mg (range 0.49-0.83 mg). All doses were sterile and free
of bacterial endotoxins.
Animal Dosimetry
The animal dosimetry is detailed in supplemental data avail-
able online. In brief, tracer uptake was predominantly retained
in the muscle, bone, and liver with a long circulation time in the
blood, leading to highest radiation dose to the heart wall
(mainly from activity in the blood pool), osteogenic cells, and
bladder wall. A relatively high amount of tracer was observed
to be excreted in the urine. Based on the animal dosimetry
results, the administered activity was conservatively selected
to be 140 MBq in order to result in an effective dose (ED) from
the radiopharmaceutical and the CT component of the PET/CT
imaging of no more than 50 mSv.
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Patient Characteristics
Eleven patients (mean 56.7 [range 21-72] years of age; 7 men,
4 women) were enrolled in the study. The patient characteris-
tics and PET results are summarized in Table 1.
Safety Evaluation
The mean (SD) administered activity was 135 (21) MBq (3.64
[0.56] mCi; range 88-155 MBq). There were no adverse or
clinically detectable pharmacological effects in any of the 11
patients. No significant changes were observed in vital signs or
inthe results of laboratory studies or electrocardiograms.
Positron Emission Tomography–Computed Tomography
Biodistribution and Dosimetry
All patients except 1 underwent 3 imaging sessions; that 1
patient missed his first imaging session because of another
appointment. Minimal to mildly increased 124I-PGN650 tumor
uptake was seen in 9 of the 11 patients. Overall, the tumor
uptake was greatest at the latest imaging session (Table 1). The
average tumor SUVmax was 4.02 (2.08) and the corresponding
T/B ratio was 0.62 (0.41;Figure 1).
Activity was observed to be retained predominantly in the
liver, spleen, and circulating blood. In some patients, a small
amount of activity was seen to accumulate in the stomach wall.
The thyroid showed only minimal uptake on the PET images.
Figure 1 shows representative whole-body images at 1 hour, 3
hours, and 48 hours postinjection. Figure 2 presents the com-
bined organ time-activity curves in the sampled organs along
with the monoexponential fits. The initial retention fractions in
the blood, liver, and kidneys were 60% of the ID, 12% ID, and
1.7% ID, respectively. A small spherical ROI covering the
thyroid (as seen on CT) was drawn. The thyroid showed low
uptake at approximately 0.08% ID. The blood showed a
relatively slow clearance half-life of 46.2 hours with percent-
age retention of 65% (20%) at* 45 minutes postinjection. The
whole-body clearance biological half-life was 87 hours.
For most organs, a rapid distribution of the tracer to the
organ is observed immediately after injection (chiefly reflect-
ing activity in blood) followed by slow clearance. Liver clear-
ance was observed with a time constant of 0.014/hour and
blood clearance was observed with a biological half-life of
46 hours. Organ residence times are presented in Table 2 and
the human radiation dose estimates are presented in Table 3.
Because of its high retention, the liver is the organ receiving the
greatest radiation dose (0.77 mGy/MBq; 2.59 rad/mCi). The
gender-averaged ED was 0.41 mSv/MBq (1.52 rem/mCi).
Discussion
Positron emission tomography was chosen for PS imaging
because of its high spatial resolution, high sensitivity, and
quantitative capability. Several positron-emitting radionuclides
were considered for PGN650 labeling, ranging in half-life from
minutes to days. Matching of the radionuclide half-life to the
pharmacokinetic profile of PGN650 was an important criterion
for radionuclide selection. Feasible radiochemical labeling of
PGN650 was also a key criterion. Taking these and other cri-
teria (eg, availability, cost, and prior preclinical experience)
into account, 124I was chosen for PGN650 labeling, despite the
fact that its physical half-life (100.22 hours) is longer than
would be predicted to be necessary given a biological half-
life of PGN650, based on mouse biodistribution data of approx-
imately 15 hours. Secondly, there are several well-understood
methods for labeling antibodies and other biomolecules with
iodine radionuclides, including 124I. Importantly, there is sub-
stantial reported experience on the use of 124I for radiolabeling
and molecular imaging in humans.20-28 In addition, microPET
imaging with 124I-PGN650 in a rat tumor model demonstrated
definite tumor uptake of this tracer at 24 and 48 hours with
Table 1. Patient Demographic and Individual Patients PET Results.
Patient No./Age/
Gender Cancer Type/Target Lesion Location
Highest Visual
Uptake
Tumor SUVmax Blood SUVmean
1 hour 3 hours 24/48 hours 1 hour 3 hours 24/48 hours
1/62/M Esophageal cancer/mediastinal lymph
node
None 0.54 0.19 0.31 16.44 10.17 7.70
2/67/F Gastrointestinal primary/pelvic mass Mild 4.90 7.20 9.10 10.0 8.40 6.44
3/56/M Esophageal cancer/primary tumor Mild 5.50 5.20 6.19 10.05 8.76 5.34
4/21/M Ewing sarcoma/iliac mass Minimal 2.90 4.33 5.52 5.31 6.71 3.08
5/61/M Malignant melanoma/thigh soft tissue
mass
Mild 4.70 5.13 4.03 10.60 8.19 4.06
6/65/M Colon cancer/iliac lymph node None 1.49 1.33 1.36a 6.27 7.29 2.23a
7/59/M Lung cancer/primary tumor Mild 6.10 4.49 4.45 10.71 10.86 9.55
8/54/F Lung cancer/primary tumor Mild ND 2.5 2.2 ND 7.83 5.26
9/66/F Hemangiosarcoma/llung mass Minimal 4.30 4.22 2.90 11.90 10.60 6.55
10/68/M Pleomorphic liposarcoma/pleural mass Mild 5.70 3.70 6.91 10.52 8.62 6.11
11/33/M Osteosarcoma/thigh mass Mild 3.64 3.44 4.25 3.35 2.92 4.91
Abbreviations: F, female; M, male; ND, imaging was not done; PET, positron emission tomography; SUVmax, maximum standardized uptake value.
aImaging performed 4 days after injection.
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acceptable nonspecific background localization, further sup-
porting the rationale for use of 124I-PGN650 imaging in
humans with cancer. Although radioiodine-labeled biomole-
cules can suffer from in vivo deiodination, 124I-PGN650
demonstrated little deiodination in the rat tumor model after
potassium iodide blocking.14 This is consistent with the lack of
internalization of PS-binding antibodies in vivo and, thus, the
inaccessibility to intracellular enzymes that can lead to deiodina-
tion. To our knowledge, there are no data about the pharmacoki-
netics of unlabeled PGN650. The mass of 124I incorporated into
an administered dose of PGN650 is approximately 4 ng, which is
negligible compared to the mass of the PGN650 itself, and will
not affect its pharmacokinetics. The results of the immunobinding
assays also support the contention that there is a minimal effect
of 124I on the binding and biodistribution of PGN650.
The manufacturing process of 124I-PGN650 was optimized
to improve antigen-binding potency after it was determined
that the initial manufacturing conditions (used to prepare drug
product for the first 4 patients of this study) overoxidized
PGN650, resulting in low immunoreactivity (antigen binding).
Once these conditions were optimized, the immunoreactivity of
PGN650 was found to be >85%, more comparable to that of
unlabeled PGN650. However, improvement in immunoreactiv-
ity did not improve tumor uptake, likely due to the fact that
tumor PS level was not increased. Increase in PS levels, which
is expected to improve tumor uptake, typically occurs when
therapy is combined with imaging. This was not the case in
this trial.
Despite successful imaging in animal tumor models, we did
not observe similar results in humans; the tumor uptake was
quite low and not sufficient for clinical studies. The optimiza-
tion of 124I-PGN650 immunoreactivity, described above, did
not have any discernible effect on tumor uptake. This low
uptake, irrespective of improved immunoreactivity, is likely
related, at least in part, to the fact that our patients had not had
tumor-directed systemic or radiation therapy for a median of 26
days (range 5-526 days) before administration of 124I-PGN650
per protocol, and thus PS exposure in the tumor did not
increased above baseline. However, despite the low tracer
uptake observed, the use of this approach may be relevant in
future studies that include imaging before therapy, by compar-
ison with that after therapy, where the apoptotic signal should
increase if therapy is effective. A smaller antibody fragment
than F(ab0)2, such as a minibody, might make the approach
more optimal.
The tracer circulation in the blood was observed to follow a
single exponential clearance function with half-life of 46.2
hours and a percentage uptake of 65% (20%) at* 45 minutes
Figure 1. Representative whole-body positron emission tomography images of 124I-PGN650 immediately after injection and at 3 and 48 hours’
delay. Tumor uptake is observed in the left proximal thigh, see panels b and c.
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postinjection. Thus, the tracer stayed in the circulation for a
sufficient time to reach and bind to the tumor. However, PS is
normally expressed at low levels on tumor cells but becomes
overexpressed in response to therapy that causes apoptosis.
Because of the relatively long intervals between systemic or
radiation therapy and imaging in our patients, the expression of
PS in the tumors would be expected to be low, leading to low
tumor uptake.
We evaluated the human radiation dosimetry, as well as the
safety and imaging characteristics, of 124I-PGN650 in an
Figure 2. Cumulative organ time-activity curves obtained by collating data from all organ tracer retention from all 11 patients.
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animal study and, subsequently, in patients. Human dosimetry
estimates derived from murine biodistribution data were used
to select the target ID for this human study. These data indi-
cated a critical organ dose of 0.37 mGy/MBq (males or
females) to the heart wall (reflecting the long retention time
of the tracer in the blood in humans) and an average ED of 0.28
mSv/MBq (gender averaged males and females). Thus, the
total ED for 3 PET/CT imaging time points for dosimetry eva-
luation (for 140 MBq of 124I-PGN650 and 3 low-dose CT
scans) was estimated to be below 50 mSv based on the pre-
clinical dosimetry data. Since imaging is performed only up to
24 to 48 hours postinjection, 64Cu might have been a better
alternative to 124I and would have allowed for lower radiation
dose. However, for consistency with the previous preclinical
studies using 124I and 125I, performed by the sponsor, we con-
tinued this clinical phase 0 study using the same radiolabel.
There were substantial differences between the mouse-
based dosimetry extrapolated to humans and the human-
based dosimetry (see Figure 3, online supplement), especially
for the heart wall, kidneys, liver, and spleen. The average ED of
approximately 0.28 mSv/MBq (1.04 rem/mCi) based on mouse
data was lower than that based on the human data. Presumably
because of the different metabolism in mice as compared to
human, the tracer was observed to clear faster from the blood
and was eliminated in greater proportion in urine in mice,
resulting in a lower circulation time and lower liver and spleen
uptake. Extrapolation of mouse dosimetry to human is not
meant to provide an exact prediction of human radiation dose,
but an estimate of the safe injection level for human studies.
In the human study, we observed overall longer tracer resi-
dence times in all organs. Notably the liver, kidney, and heart
muscle (estimated from blood content) residence times are
higher in humans, indicating slower kinetics in humans relative
to rodents. Supplemental Figure S1 presents the comparative
dosimetry of the animal data against the present human
Table 4. Comparison of Effective Dose From 124I-PGN650 to Other
Tracers Labeled With 124I and to Other Common Nuclear Medicine
Radiopharmaceuticals.
Tracer Effective Dose, mSv/MBq














ASTM, diacetyl-bis(N4-methylthiosemicarbazone, DOTA, 1,4,7,10-tetraazacy-
clododecane-1,4,7,10-tetraacetic acid, FDG, fluorodeoxyglucose.
Table 3.Organ Radiation Doses for 124I-PGN650 and Effective Dose
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Uterus 0.18 0.26







Abbreviation: PET/CT, positron emission tomography/computed
tomography.
Table 2. Organ Residence Time in Hour Derived From Whole PET/
CT Image Data.













Remainder of body 13.9
Abbreviation: PET/CT, positron emission tomography/computed tomography.
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dosimetry. Because of the relatively long half-life of 124I and
the slow clearance of the tracer in the blood, the dose to the
kidneys, spleen, heart wall, and liver were determined to be
approximately 0.75 mGy/MBq and the gender-averaged ED to
be 0.41 mSv/MBq. An average radiation dose to the thyroid of
0.82 mGy/MBq was observed due, in part, to the thyroid blood
content and also by a possible slight in vivo deiodination of the
tracer in humans despite thyroid blockage with potassium
iodide. It is therefore possible that deiodination is underesti-
mated, thus explaining the high urine excretion. These radia-
tion doses are similar to those of other cancer imaging agents
labeled with 124I20 but are somewhat higher than those labeled
with other radionuclides (Table 4). Patient imaging can, how-
ever, be performed safely with an injected dosage of as little as
74 MBq (2 mCi). 124I-PGN650 was thus found to be safe for
human imaging in this phase 0 study and no adverse effects was
observed in any of our 11 patients.
Conclusion
124I-PGN650 was shown to be safe for human imaging of PS, a
marker of the tumor microenvironment. No adverse events
were observed in the patients studied. The liver was the organ
receiving the highest radiation dose at 0.77 mGy/MBq; and the
gender-averaged ED was estimated at 0.41 mSv/MBq. How-
ever, tumor targeting with this agent in patients was less than
previously observed in animal studies.
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